Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.

Abstract

Forty-six patients with histologically confirmed lung cancer received treatment with the cytotoxic drug VP-16-213 in a dose of 100 mg twice daily, given orally for five days. The overall objective response rate was 11 out of 46 (24%) or 11 of the 33 (33%) who survived to receive two cycles. The drug was effective in all histological types. Only one patient developed leucopenia. This demonstration of the safety of VP-16-213 and its effectiveness suggested that this drug might be used in combination chemotherapy. A series of pilot studies showed unexplained marrow toxicity when VP-16-123 combined with vincristine was given with either methotrexate of adriamycin.

• Authors: G Anderson, F Bowyer, L Williams
• Journal: Thorax (Thorax) Vol. 36 Issue 6 Pg. 462-4 (Jun 1981) ISSN: 0040-6376 [Print] England
• PMID: 7314017 (Publication Type: Journal Article)

Chemical References

• Vincristine
• Etoposide
• Doxorubicin
• Podophyllotoxin
• Methotrexate

Topics

• Bone Marrow Diseases (chemically induced)
• Doxorubicin (therapeutic use)
• Drug Therapy, Combination
• Etoposide (adverse effects, therapeutic use)
• Humans
• Lung Neoplasms (drug therapy)
• Methotrexate (adverse effects, therapeutic use)
• Podophyllotoxin (analogs & derivatives)
• Vincristine (therapeutic use)